Rapid test plus targeted antibiotic shows promise for tough infections in blood cancer patients
NCT ID NCT04673175
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether the antibiotic ceftolozane-tazobactam, guided by a rapid molecular test, could effectively treat serious Pseudomonas aeruginosa infections in people with blood cancers or those who had a stem cell transplant. The 17 participants received the antibiotic through a vein for 10 to 14 days. The study was terminated early, so results are limited, but researchers aimed to see if patients were alive and infection-free 30 days later.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ceftolozane-tazobactam (Zerbaxa), an antibiotic given through a vein
What this could lead to
If successful, this could show that using a rapid test to quickly match the right antibiotic improves survival and recovery for vulnerable patients with blood cancers.
What could go wrong
The study was terminated early with only 17 participants, so it cannot provide strong evidence. The historical control group also limits how much we can trust the results.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMONIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Weill Cornell Medicine
New York, New York, 10065, United States